It is with an existing client working on a trial of a drug for the rare neurodegenerative condition Spinocerebellar Ataxia type 3 (SCA3), also known as Machado-Joseph disease.
Currently, there is no treatment to slow down or reverse the progressive course of this terminal condition.
"SCA3 is an area with clear, unmet medical needs and we are delighted to be chosen as the neuroimaging partner in this spinocerebellar ataxia trial,” said IXICO chief commercial officer Lammert Albers in a statement.
The company will provide operational services and advanced AI neuroimaging for volumetric, diffusion and functional magnetic resonance as well as magnetic resonance spectroscopy and quantitative susceptibility mapping.
“Neuroimaging, with its unique ability to reveal extraordinary information about the structural and functional characteristics of the human brain is a powerful tool in CNS studies, and we are proud to support our clients in potentially unlocking new insights into disease progression," added Albers.